Forum: Financial Investment Forum. - Discuss Stocks, Cryptocurrency, And Other Financial Investments

Thread: Read if you want one stock you can retire on

Page 12 of 12 FirstFirst ... 3456789101112
  1. #276  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,674
    Pete Najarian https://www.cnbc.com/pete-najarian/

    Co-Founder, MarketRebellion.com
    • Disclosures as of 10/8/19:
      Long calls: Activision, Ally Financial, Altria Group, AT&T, Barrick Gold Corp, BP, Bristol-Myers Squibb, CISCO, CITI, Discovery, Freeport-McMoRan, Garena, Intel, Icandy Interactive, Johnson Controls International PLC, Marathon Petroleum, MGM Resorts, Oasis Petroleum, Occidental Petroleum, Petmeds, Petroleo Brasil, Salesforce, Snap, Sunrun Inc., TRI Pointe Group, United States Natural Gas Fund, VanEck Vectors Gold Miners ETF, VF Corp, W. P. Carey Inc., Vistra Energy Corp., Wells Fargo, Whiting Petroleum, WPX Energy Inc., X-trackers Harvest, XInhua China 25 index
      Long stock: 3M, Apple, Bank of America, Canada Goose, Casey’s General Stores, CitiGroup, The Coca-Cola Co, CryoPort Inc, ExxonMobil, Facebook, H.B.Fuller, IBM, Intel, Kinder Morgan, Las Vegas Sands, Luckin Coffee, Lululemon Athletica, Marathon Petroleum, Merck & Co., Micron Technology, Microsoft, Netflix, PepsiCo, Pfizer, Predictive Technology Group, Restaurant Brands International, Revolve Group, Royal Caribbean Cruises, Southwest Airlines, Target, United Parcel Service, United Airlines Holdings, Upwork, U.S. Bancorp, The Walt Disney Company, Wells Fargo, Wynn Resorts.
      Owns puts: General Electric Company.
    Reply With Quote  
     

  2. #277  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,674
    8k Filing https://www.sec.gov/Archives/edgar/d...2019form8k.htm

    "Deloitte becoming PRED's auditor occurred after many months of due-diligence, including reviewing SEC filings, PRED's financial statements and accounting practices, operations, and conducting a lengthy and detailed review of the false claims within Hindenburg. No global accounting firm would become PRED's auditor if the allegations (many on this board) against PRED were false, misleading, or inaccurate, including false SEC filings, insider trading and self-dealing, and the other negative bashing was even partly accurate. Deloitte does not become the auditor for bad actors because of the obvious legal and financial liabilities. Click to Deloitte's Audit Committee Resource Guide to understand compliance requirements that had to be in place for Deloitte to become PRED's auditor" Thomas
    Reply With Quote  
     

  3. #278  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,674


    Predictive Laboratories Announces Commercialization And Full Market Availability Of ARTguide™ At American Society Of Reproductive Medicine (ASRM) Scientific Congress And Expo

    Company also presenting two oral and one poster scientific presentations at ASRM

    Email Print Friendly Share
    October 10, 2019 08:00 ET | Source: Predictive Technology Group, Inc.


    SALT LAKE CITY, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on hard-to-detect diseases, women’s health and infertility, announces the commercialization and full market availability of ARTguide, the first integrated, DNA-based test that evaluates the risk for endometriosis and other genetic causes of infertility in women. After a successful beta launch, Predictive Laboratories completed a laboratory expansion that will allow ARTguide to now be available in fertility clinics across the United States.
    “Endometriosis can be a debilitating disease for many women as it can cause severe pelvic pain, inflammation, adhesions to the fallopian tubes and uterus, and often, infertility,” said Kenneth Ward, M.D., Laboratory Director of Predictive Laboratories. “Nearly 50% of women who struggle with infertility have endometriosis, but because surgery is required for a definitive diagnosis, oftentimes it remains undiagnosed. ARTguide can predict a patient’s risk of endometriosis early on so that women have a better understanding of their barriers to conception, and therefore their physician can create a more personalized infertility treatment plan.”
    ARTguide provides a greater understanding of over a dozen genetic conditions affecting a woman’s fertility by identifying previously invisible barriers to conception and improving success rates in assisted reproductive technologies (ART), such as in vitro fertilization (IVF). ARTguide tests for hundreds of genetic markers of endometriosis and 80 other additional mutations causing conditions such as ovarian failure, that may impact fertility. Through the identification of genetic infertility risk factors, ARTguide helps women optimally navigate their path towards conception and a healthy birth. ARTguide is appropriate for all women considering use of ART to overcome difficulty conceiving or carrying a pregnancy.
    ARTguide’s full market availability will be announced during the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress and Expo, Oct. 12 - 16 in Philadelphia. In addition to sharing this news, Dr. Ward, a board-certified physician in obstetrics and gynecology, perinatology, clinical genetics and molecular genetics, will present two scientific papers at ASRM. The schedule of his speaking engagements are as follows:

    • Wednesday, Oct. 16 at 6:30 a.m. ET — Poster presentation: Endometriosis risk allele in WNT4 may interact with rare mutations in HDAC2 gene
    • Wednesday, Oct. 16 at 11:15 a.m. ET — Oral abstract: Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk

    Dr. Ward’s colleague, Hans Albertsen, Ph.D., will present additional endometriosis data on Wednesday, Oct. 16 at 11:30 a.m. ET — Oral abstract: Cytoskeletal and extracellular matrix genes are key contributors in the pathogenesis of endometriosis.
    About Predictive Laboratories
    Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive Laboratories offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive Laboratories enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis.
    The Company’s proprietary tests include ARTguideTM and FertilityDXTM. ARTguide is a blood test that assesses a woman’s endometriosis risk and other genetic causes of infertility in order to optimally navigate the path towards conception. FertilityDX is a comprehensive test and service, using the parental genetic assessment as the map to guide the journey to successful pregnancy and a healthy newborn. Predictive Laboratories’ tests are processed at the Company’s state-of-the-art CAP-accredited, CLIA-certified laboratory, equipping physicians with the robust diagnostic tools to provide personalized treatment for their patients. For more information, visit www.predictivelabs.com.
    About Predictive Technology Group, Inc.
    Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
    Forward-Looking Statements:
    To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
    Media Contact:
    Holly Dugan
    predictive@antennagroup.com
    201-465-8019
    Investor Contact:
    LHA Investor Relations
    Jody Cain
    jcain@lhai.com
    Kevin McCabe
    kmccabe@lhai.com
    310-691-7100

    Reply With Quote  
     

  4. #279  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,674
    + Font Resize -
    Predictive Technology introduces PGxPLUS+ pharmacogenomic test
    Salt Lake City
    Saturday, October 12, 2019, 13:00 Hrs [IST]
    Predictive Technology Group, Inc, a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces that its wholly owned subsidiary Predictive Laboratories, Inc. has commercially launched PGxPLUS+, a pharmacogenomic test panel being marketed to pain clinics for patients with chronic pain.

    PGxPLUS+ evaluates genetic factors that play a major role in an individual’s response to medications. In parallel, Predictive Laboratories has reached a milestone of enrolling 350 patients with chronic pain into an Investigational Review Board-approved clinical study aimed at providing additional insight into the mechanisms of chronic pain and responses to pain therapies.

    Predictive Technology Group is tackling chronic pain and the opioid crisis on multiple fronts. Predictive has already developed and in-licensed important prognostic DNA tests and novel treatments for osteoarthritis, lumbar disc disease, endometriosis, and other conditions causing chronic pain. In 2016, the Institute of Medicine estimated that up to one-third of the US population lives with ongoing pain. Chronic pain is often triggered by one of these common conditions, and over time can develop into a chronic pain syndrome, which is a disease itself.

    The PGxPLUS+ panel is one of the most comprehensive pharmacogenetic tests available on the market. Predictive’s test evaluates 112 genetic variants across 38 genes that affect the metabolism of over 150 common medications, including pain medications. More than 90% of the population has one or more gene variants that affect the efficacy or safety of prescription drugs. Variation in drug metabolism is largely determined by an individual’s genetic profile, blood levels of a drug may vary up to 1,000-fold in similar patients taking identical doses of the same drug. Pharmacogenomics is the study of the role of our genome in drug responses.

    Dr. Bryt Christensen, M.D., a pain specialist, reports, “The PGxPLUS+ pharmacogenetic test has been very helpful in my day-to-day practice. The results give insights into why some patients are not responding to medications as expected. With the help of these test results, I have been able to start or switch medications for patients more successfully. The PGxPLUS+ test helps me avoid prescribing medications that a patient won’t metabolize well, leading to better and more personalized patient care.”

    One-third of patients taking long-term opioid therapy for non-cancer chronic pain either find their medication to be ineffective or they do not tolerate the side effects of the treatment. In the clinical study, Predictive is testing patients who are taking high doses of opioids [=50 morphine milligram equivalents (MME)/day] for genetic variants responsible for their underlying disease, their metabolism of opioids, their intrinsic pain thresholds, and any genetic predisposition to opioid addiction. Predictive plans to develop more comprehensive treatment guidelines for pain based on predictive genetic markers.

    “The ability to effectively treat individuals in pain represents a significant market opportunity and of even greater importance it serves an obligation of society to alleviate the current pain and suffering of an individual in a safer and more effective manner,” said Bradley Robinson, CEO of Predictive Technology Group. “Our company is both identifying the most effective ways to treat pain at a personalized level and working to understand the underlying cause of diseases like osteoarthritis, lumbar disc disease and endometriosis to treat or prevent the root cause of the pain. We are pleased to add the PGxPLUS+ test to our portfolio of regenerative medicine and diagnostic products focused on treating chronic pain diseases.”
    http://www.pharmabiz.com/NewsDetails...d=118726&sid=2
    Reply With Quote  
     

  5. #280  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,674

    Predictive Laboratories Launches FertilityDX™


    Genetic testing service now available to identify causes of infertility and guide personalized fertility treatments

    EmailPrint FriendlyShare
    October 14, 2019 08:00 ET|Source:Predictive Technology Group, Inc.


    SALT LAKE CITY, Oct. 14, 2019 (GLOBE NEWSWIRE) --Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on hard-to-detect diseases, women’s health and infertility, announces the launch of FertilityDX™, a comprehensive genetic testing service that identifies barriers to healthy pregnancy and birth, allowing doctors to tailor fertility treatments. The test launch will be formally announced at theAmerican Society for Reproductive Medicine (ASRM) 2019 Scientific Congress and Expo, Oct. 12-16 in Philadelphia.
    “For the one in eight couples who struggle with infertility, trying to have a child can be financially, physically and emotionally exhausting—largely because the couple doesn’t knowwhythey are having difficulty conceiving,” said Kenneth Ward, M.D., Laboratory Director of Predictive Laboratories. Dr. Ward is a board-certified physician in obstetrics and gynecology, perinatology, clinical genetics and molecular genetics. “Our desire is to arm couples considering assisted reproductive technologies (ART) with an understanding of the genetic and medical obstacles that may be affecting their fertility and provide doctors with genetically relevant information to help their patients have a healthy baby.”
    FertilityDX provides information by evaluating three key areas: contributors to (or causes of) infertility, risks of pregnancy complications, and risks for serious genetic conditions in offspring.
    FertilityDX supports both physician and patient throughout the entirety of the treatment process. Patients are provided with pretest counseling and clear and relevant test results. Physicians get an easy-to-understand final report and access to a variety of genetics consultants. The test will be launched in select fertility clinics across the United States, offering couples access to the most comprehensive genetic service to date.
    About Predictive Laboratories
    Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive Laboratories offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive Laboratories enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis.
    The Company’s proprietary tests include ARTguideTMand FertilityDXTM. ARTguide is a blood test that assesses a woman’s endometriosis risk and other genetic causes of infertility in order to optimally navigate the path towards conception. FertilityDX is a comprehensive test and service, using the parental genetic assessment as the map to guide the journey to successful pregnancy and a healthy newborn. Predictive Laboratories’ tests are processed at the Company’s state-of-the-art CAP-accredited, CLIA-certified laboratory, equipping physicians with the robust diagnostic tools to provide personalized treatment for their patients. For more information, visitwww.predictivelabs.com.
    About Predictive Technology Group, Inc.
    Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, to support a patient from diagnosis through treatment. The companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visitwww.predtechgroup.com.
    Forward-Looking Statements:
    To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
    Media Contact:
    Holly Dugan
    predictive@antennagroup.com
    201-465-8019
    Investor Contacts:
    LHA Investor Relations
    Jody Cain
    jcain@lhai.com
    Kevin McCabe
    kmccabe@lhai.com
    310-691-7100


    Reply With Quote  
     

  6. #281  
    RX Local MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    15,238
    Hopefully this is our week to take off again...

    It's almost presentation time...
    Reply With Quote  
     

  7. #282  
    Everybody Got Dey Cups But Dey Ain't Chipped In.... RapStar's Avatar
    Join Date
    Dec 2004
    Location
    West Palm
    Posts
    742
    Quote Originally Posted by MattyMatt View Post
    Hopefully this is our week to take off again...

    It's almost presentation time...
    No doubt!
    Reply With Quote  
     

  8. #283  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,674





    Predictive Technology Group Engages CLSA Capital Markets Limited, a CITIC Securities Company, to Support Product Launches into China’s Rapidly Growing Women’s Health and Fertility Market

    October 15, 2019 09:00 ET | Source: Predictive Technology Group, Inc.

    SALT LAKE CITY, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the development of genetic and molecular diagnostics and companion therapeutics, announces that it has engaged CLSA Capital Markets Limited, a CITIC Securities Company, to provide introductions to potential strategic partners and regulatory guidance to support the launch of its proprietary genetic-based products into China’s (PRC) rapidly growing markets for women’s health and fertility. Terms of the transaction were not disclosed.


    “Given our genetic library, research and understanding of genetics, endometriosis and other factors that may affect a woman’s fertility, we are excited to bring our noninvasive testing technology to this large, emerging market that already surpasses the U.S. in terms of the number of affected women,” said Bradley Robinson, Chief Executive Officer of Predictive Technology Group. “Our tests help both the doctor and patient understand and navigate the barriers to fertility, changing the path to a healthy baby. We are especially pleased to collaborate in this endeavor with CLSA, a leading capital markets and investment group in Asia.”


    Predictive expects to introduce ARTguide™ among other fertility diagnostics to the Chinese market. On October 14, 2019, Predictive launched the full U.S. market availability of ARTguide, its test to evaluate the risk for endometriosis and other genetic causes of infertility in women, at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress and Expo in Philadelphia.


    In 2016 the National Health and Family Planning Commission of the PRC reported that 40 million Chinese couples were experiencing fertility issues. Similarly, the American Society for Reproductive Medicine (ASRM) reported in 2017 that an estimated 25% of Chinese women of childbearing age struggled with infertility issues. In 2018 the European Society of Human Reproduction and Embryology estimated that approximately 800,000 assisted reproductive technology (ART) cycles, such as in vitro fertilization (IVF), were being performed in China annually. Chinese women are driving the fertility markets both in China and medical tourism industries overseas. The global IVF market is expected to grow at an annual rate of 10.2% and to reach $36.2 billion by 2026. The U.S. Center for Disease Control reported that of the patients who sought fertility care in 2017, 284,385 ART cycles were performed resulting in 78,052 live born infants with ART accounting for 1.7% of all infants born in the U.S. annually.


    Predictive Laboratories ARTguide Test

    ARTguide is the first integrated, DNA-based test that evaluates the risk for endometriosis and other genetic causes of infertility in women. It provides a greater understanding of over a dozen genetic conditions affecting a woman’s fertility by identifying previously invisible barriers to conception, consequently improving ART success rates. ARTguide is appropriate for all women considering use of ART to overcome difficulty conceiving or carrying a pregnancy.


    ARTguide was introduced to a limited number of U.S. clinics in 2018. Predictive Laboratories is a wholly owned molecular and genetic diagnostics company of Predictive Technology Group focused on hard-to-detect diseases, women’s health and infertility. Predictive Laboratories recently completed a laboratory expansion to add capacity that allows ARTguide to be available more broadly in the U.S.


    Endometriosis

    Endometriosis is an estrogen-responsive, chronic condition that arises from extra-uterine growth of the stromal or glandular tissue that line the uterus. Often called the “invisible disease,” endometriosis affects an estimated 1 in 10 women in the U.S. during their reproductive years with many cases go undiagnosed. It is common for a woman to experience symptoms—such as chronic pelvic pain, heavy or painful periods—for a decade or more before a diagnosis is made (13 years, on average, in China). The current standard for diagnosis is laparoscopic surgery, to biopsy lesions found within the fallopian tubes or uterus. Even with this surgery, intraoperative diagnosis by conventional laparoscopic visualization is frequently difficult and inaccurate.


    Severe endometriosis with extensive scarring and organ damage is one of the most common causes of female infertility. However, endometriosis can still affect fertility when no symptoms are present. 30% to 50% of women with endometriosis may experience infertility, and 25% to 50% of women who experience infertility have endometriosis.


    Studies have linked the risk of endometriosis to ethnicity, with several reporting Asian women’s risk being nine times greater than that of Caucasian women. A recent systematic review analyzing the outcomes of more than 1.9 million Chinese women found endometriosis to be associated with the worsening of obstetric and pregnancy-related outcomes, including miscarriage, pre-term labor, placenta previa, small for gestational age, and caesarean delivery compared to healthy controls.


    Predictive Laboratories, Inc.

    Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis. For more information, visit www.predictivelabs.com.


    Predictive Technology Group, Inc.

    Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.


    CLSA Capital Markets Limited
    CLSA is Asia’s leading capital markets and investment group, providing global investors with insights, liquidity, and capital to drive their investment strategies. Award-winning research, an extensive Asia footprint, direct links to China, and highly experienced finance professionals differentiate our innovative products and services in asset management, corporate finance, capital, and debt markets, securities, and wealth management. As the international platform of CITIC Securities (SSE: 600030, SEHK: 6030), China’s largest investment bank, CLSA is uniquely positioned to facilitate cross-border capital flows and connect China with the world and the world to China. Founded in 1986 and headquartered in Hong Kong, CLSA’s global network spans 21 locations across Asia, Australia, Europe, and the United States. For more information, visit www.clsa.com.


    Forward-Looking Statements

    To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.


    Contacts

    For more information, visit www.predtechgroup.com or contact Investor Relations:


    Media Contact

    Holly Dugan

    predictive@antennagroup.com

    201-465-8019


    Investor Contact

    LHA Investor Relations

    Jody Cain jcain@lhai.com

    Kevin Mc Cabe kmccabe@lhai.com

    310-691-7100

    Reply With Quote  
     

  9. #284  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,674


    Predictive Laboratories Team Led by Laboratory Director Kenneth Ward, M.D. Receives 2019 Endometriosis Special Interest Group Prize Paper Award

    Research presented by Dr. Hans Albertsen of Juneau Biosciences advancing knowledge of the genetic factors contributing to endometriosis receives award at the 2019 American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo

    Email Print Friendly Share
    October 17, 2019 09:00 ET | Source: Predictive Technology Group, Inc.


    SALT LAKE CITY , Oct. 17, 2019 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on hard-to-detect diseases, women’s health and infertility, announces Kenneth Ward, M.D., laboratory director of Predictive Laboratories and chief executive officer of Juneau Biosciences; Rakesh Chettier M.S., director of biostatistics of Predictive Laboratories; and Hans Albertsen, Ph.D., chief scientific officer of Juneau Biosciences, have received the 2019 Endometriosis Special Interest Group (EndoSIG) Prize Paper in the “Best in Clinical/Population Science” category.
    Dr. Albertsen’s presentation entitled “Cytoskeletal and extra cellular matrix genes are key contributors in the pathogenesis of endometriosis” was delivered at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress & Expo in Philadelphia on October 16. EndoSIG is a member group of ASRM aimed at fostering increased interest in the biology, pathophysiology and clinical management of endometriosis.
    “We are honored to receive this prestigious award from the ASRM Research Committee,” said Dr. Albertsen. “As endometriosis is generally characterized as a hormonal and inflammatory disease, current therapies often come with significant debilitating side effects. The scientific breakthroughs reported in these award-winning discoveries provide Predictive with insights into new non-hormonal therapies.”
    The team’s research is based on the genetic markers of endometriosis discovered by Juneau and Predictive scientists in recent years, and uncovers molecular pathways involved in the pathogenesis of endometriosis-induced lesions in women at risk for the disease. Juneau’s gene discovery work in endometriosis was also awarded the EndoSIG Prize Paper in 2015 and 2018.
    Dr. Ward, a board-certified physician in obstetrics and gynecology, perinatology, clinical genetics and molecular genetics, presented two scientific papers at the Annual ASRM meeting: a poster entitled, “Endometriosis risk allele in WNT4 may interact with rare mutations in HDAC2 gene” and an oral abstract entitled, “Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk.”
    “We are tremendously proud of Drs. Ward and Albertsen and the teams at Predictive Laboratories and Juneau Biosciences for their research, collaborations and continued devotion to endometriosis and other gene discoveries that advance our understanding of fertility and women’s health, and lead to healthy newborns,” said Bradley Robinson, chief executive officer of Predictive Technology Group. “ASRM brings leaders in reproductive care together from across the world to share findings, inspire new methodology and encourage collaboration to promote further development in reproductive medicine.”
    In June 2019, Predictive Laboratories and Thermo Fisher Scientific announced a global research collaboration to study underlying genetic factors contributing to female infertility. The two companies conducted meetings at ASRM in Philadelphia. This partnership pairs Predictive’s innovative research and development capabilities with Thermo Fisher’s market-leading next generation sequencing technology and analytical capabilities to accelerate the understanding of the genetics affecting infertility for future development of diagnostic solutions.
    About Predictive Laboratories
    Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive Laboratories offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive Laboratories enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis.
    The Company’s proprietary tests include ARTguideTM and FertilityDXTM. ARTguide is a blood test that assesses a woman’s endometriosis risk and other genetic causes of infertility in order to optimally navigate the path towards conception. FertilityDX is a comprehensive test and service, using the parental genetic assessment as the map to guide the journey to successful pregnancy and a healthy newborn. Predictive Laboratories’ tests are processed at the Company’s state-of-the-art CAP-accredited, CLIA-certified laboratory, equipping physicians with the robust diagnostic tools to provide personalized treatment for their patients. For more information, visit www.predictivelabs.com.
    About Predictive Technology Group, Inc.
    Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
    Forward-Looking Statements:
    To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
    Contacts
    For more information, visit www.predtechgroup.com or contact Investor Relations:
    Media Contact
    Holly Dugan
    predictive@antennagroup.com
    201-465-8019
    Investor Contact
    LHA Investor Relations
    Jody Cain jcain@lhai.com
    Kevin Mc Cabe kmccabe@lhai.com
    310-691-7100

    Reply With Quote  
     

Posting Permissions
  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •